000908.SZ SHZ
Hunan Jingfeng Pharmaceutical Co.,Ltd.
1W: -1.8%
1M: -7.1%
3M: -4.2%
YTD: -10.2%
1Y: -0.2%
3Y: +133.1%
5Y: +18.1%
¥5.99 ($0.89)
+0.04 (+0.67%)
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ETF Exposure
Balance Sheet Trends
Total Assets
$940M
-11.4% ▼
5Y CAGR: -26.4%
Total Liabilities
$955M
-21.3% ▼
5Y CAGR: -16.9%
Shareholders Equity
$82M
+265.3% ▲
5Y CAGR: -44.7%
Cash & Investments
$86M
+549.6% ▲
5Y CAGR: -26.7%
Total Debt
$198M
-66.6% ▼
5Y CAGR: -34.9%
Net Debt
$113M
-80.6% ▼
Assets vs Liabilities & Equity
Year-over-Year Growth
View Full Balance Sheet
| Line Item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
| — Assets — | |||||
| Cash | $164M | $172M | $181M | $13M | $86M |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0 |
| Cash & ST Investments | $164M | $172M | $181M | $13M | $86M |
| Net Receivables | $465M | $217M | $197M | $118M | $82M |
| Inventory | $232M | $155M | $120M | $65M | $44M |
| Other Current Assets | $160M | $133M | $73M | $15M | $11M |
| Total Current Assets | $1.0B | $678M | $571M | $214M | $227M |
| Property, Plant & Equip. | $1.0B | $726M | $566M | $434M | $329M |
| Goodwill & Intangibles | $317M | $243M | $237M | $168M | $164M |
| Long-Term Investments | $270M | $111M | $50M | $45M | $0 |
| Other Non-Current Assets | $3M | $10M | $15M | $189M | $218M |
| Total Non-Current Assets | $1.7B | $1.1B | $897M | $847M | $713M |
| Total Assets | $2.7B | $1.8B | $1.5B | $1.1B | $940M |
| — Liabilities — | |||||
| Accounts Payable | $186M | $123M | $139M | $149M | $103M |
| Short-Term Debt | $1.4B | $476M | $213M | $196M | $192M |
| Deferred Revenue | $247M | $371M | $26M | $0 | $0 |
| Other Current Liabilities | $25M | $492M | $727M | $696M | $320M |
| Total Current Liabilities | $1.9B | $1.4B | $1.1B | $1.0B | $905M |
| Long-Term Debt | -$46M | $1M | $73M | $72M | $0 |
| Other Non-Current Liab. | $15M | $72M | $59M | $91M | $24M |
| Total Non-Current Liabilities | $193M | $103M | $170M | $193M | $50M |
| Total Liabilities | $2.1B | $1.5B | $1.3B | $1.2B | $955M |
| — Equity — | |||||
| Common Stock | $417M | $417M | $417M | $417M | $417M |
| Retained Earnings | -$657M | -$821M | -$949M | -$1.2B | -$1.0B |
| Accumulated OCI | -$135M | $711M | $710M | -$306M | -$306M |
| Total Stockholders Equity | $520M | $306M | $178M | -$49M | $82M |
| Total Liabilities & Equity | $2.7B | $1.8B | $1.5B | $1.1B | $940M |
| — Key Metrics — | |||||
| Total Debt | $1.4B | $874M | $599M | $594M | $198M |
| Net Debt | $1.3B | $701M | $417M | $581M | $113M |
| Total Investments | $270M | $111M | $50M | $45M | $0 |